Features of managing patients with amiodarone-induced thyrotoxicosis in real clinical practice
https://doi.org/10.14341/serg12732
Abstract
Amiodarone is an antiarrhythmic drug that is widely used in clinical practice to control various types of arrhythmias. One of the most significant side effects of amiodarone therapy is thyroid dysfunction, which is observed in about 15–20% of patients. This article presents a clinical case of a 55-year-old patient with a paroxysmal form of atrial fibrillation, for which amiodarone therapy was performed with the development of manifest amiodarone-induced thyrotoxicosis, refractory to drug therapy with glucocorticosteroids and thyrostatics. Due to the ineffectiveness of drug therapy, a total thyroidectomy was performed, which led to a rapid resolution of thyrotoxicosis and normalization of the heart rhythm.
About the Authors
T. N. Markova
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Tatyana N. Markova, MD, Dr. Sci. (Med.), Professor
eLibrary SPIN: 5914-2890
Moscow
D. G. Beltsevich
National Medical Research Center for Endocrinology
Russian Federation
Russian Federation
Dmitriy G. Beltsevich, MD, Dr. Sci. (Med.), Professor of RAS
eLibrary SPIN: 4475-6327
Moscow
E. A. Kalinicheva
Moscow City Clinical Hospital 52
Russian Federation
Russian Federation
Evgeniia A. Kalinicheva, MD, endocrinologist
eLibrary SPIN: 5883-2551
3 Pekhotnaya str., Moscow, 123182
A. Koshkodan
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Alexandra Koshkodan, resident
Moscow
N. M-R. Salavatova
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Nuryana M.-R.Salavatova, resident
Moscow
K. A. Gaunova
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Kamila A. Gaunova, resident
Moscow
References
1. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-389. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.019927
2. Kryukov EV, Potekhin NP, Fursov AN, et al. Algorithm of management of patients treated with amiodarone depending on thyroid functional state. Clin Med. 2017;95(10):901-905. (In Russ.). doi: https://doi.org/10.18821/0023-2149-2017-95-10-901-905
3. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240-254. doi: https://doi.org/10.1210/edrv.22.2.0427
4. Censi S, Bodanza V, Manso J, et al. Amiodarone-induced thyrotoxicosis: Differential diagnosis using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR). Clin Nucl Med. 2018;43(9):655-662. doi: https://doi.org/10.1097/RLU.0000000000002207
5. Sviridenko NJu, Platonova NM, Molashenko NV, et al. Endocrine aspects of amiodarone therapy in clinical practice (follow-up and treatment algorithm for patients with thyroid dysfunction). Russian Journal of Cardiology. 2012;(2):63-71. (In Russ.).
6. Benjamens S, Dullaart RPF, Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol. 2017;177(1):9-14. doi: https://doi.org/10.1530/EJE-17-0018
7. Florek JB, Girzadas D. Amiodarone. [cited 2021, Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482154/
8. Vassallo P, Trohman RG. Prescribing amiodarone: an evidencebased review of clinical indications. JAMA. 2007;298(11):1312-1322. doi: https://doi.org/10.1001/jama.298.11.1312
9. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735-751. doi: https://doi.org/10.1016/j.beem.2009.07.001
10. Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology. 1994;134(5):2277-2282. doi: https://doi.org/10.1210/endo.134.5.8156930
11. Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodaroneinduced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171(3):363-368. doi: https://doi.org/10.1530/EJE-14-0267
12. Schaan BD, Cunha CP, Francisconi A, et al. Amiodaroneinduced thyroid dysfunction in a tertiary center in south Brazil. Arq Bras Endocrinol Metabol. 2005;49(6):916-922. doi: https://doi.org/10.1590/s0004-27302005000600010
13. Sidhu J, Jenkins D. Men are at increased risk of amiodaroneassociated thyrotoxicosis in the UK. QJM An Int J Med. 2003;96(12):949-950. doi: https://doi.org/10.1093/qjmed/hcg158
14. Zosin I, Balaş M. Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol Pol. 2012;63(1):2-9.
15. Stan MN, Ammash NM, Warnes CA, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease – a cohort study. Int J Cardiol. 2013;167(3):821-826. doi: https://doi.org/10.1016/j.ijcard.2012.02.015
16. Kinoshita S, Hayashi T, Wada K, et al. Risk factors for amiodaroneinduced thyroid dysfunction in Japan. J Arrhythm. 2016;32(6):474-480. doi: https://doi.org/10.1016/j.joa.2016.03.008
17. Grineva EN, Tsoy UA, Karonova TL, et al. Draft of the federal clinical recommendations for diagnosisi and treatment of amiodarone-induced thyroid dysfunction. Clinical and experimental thyroidology. 2021;16(2):12-24. (In Russ.). doi: https://doi.org/10.14341/ket12693
18. Campi I, Perego GB, Ravogli A, et al. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodaroneinduced thyrotoxicosis. Eur J Endocrinol. 2019;181(5):519-524. doi: https://doi.org/10.1530/EJE-19-0515
19. Kotwal A, Clark J, Lyden M, et al. Thyroidectomy for amiodarone-induced thyrotoxicosis: Mayo clinic experience. J Endocr Soc. 2018;2(11):1226-1235. (In Russ.)]. doi: https://doi.org/10.1210/js.2018-00259
20. Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab. 2012;97(10):3515-3521. doi: https://doi.org/10.1210/jc.2012-1797
21. Cappellani D, Papini P, Pingitore A, et al. Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2020;105(1):242-251. doi: https://doi.org/10.1210/clinem/dgz041
22. Tonnelier A, de Filette J, De Becker A, et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis. Eur Thyroid J. 2017;6(2):108-112. doi: https://doi.org/10.1159/000453578
23. Saïe C, Ghander C, Saheb S, et al. Therapeutic plasma exchange in refractory hyperthyroidism. Eur Thyroid J. 2021;10(1):86-92. doi: https://doi.org/10.1159/000507019
24. Tieken K, Paramasivan AM, Goldner W, et al. Therapeutic plasma exchange as a bridge to total thyroidectomy in patients with severe thyrotoxicosis. AACE Clin Case Reports. 2020;6(1):e14-e18. doi: https://doi.org/10.4158/ACCR-2019-0132
25. Simsir IY, Ozdemir M, Duman S, et al. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine. 2018;62(1):144-148. doi: https://doi.org/10.1007/s12020-018-1661-x
Supplementary files
Review
For citations:
Markova T.N., Beltsevich D.G., Kalinicheva E.A., Koshkodan A., Salavatova N.M., Gaunova K.A. Features of managing patients with amiodarone-induced thyrotoxicosis in real clinical practice. Endocrine Surgery. 2022;16(1):29-34. (In Russ.) https://doi.org/10.14341/serg12732
Views:
1218
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
